2004
DOI: 10.1023/b:brea.0000021046.29834.12
|View full text |Cite
|
Sign up to set email alerts
|

Cross-Resistance Studies of Isogenic Drug-Resistant Breast Tumor Cell Lines Support Recent Clinical Evidence Suggesting that Sensitivity to Paclitaxel may be Strongly Compromised by Prior Doxorubicin Exposure

Abstract: Less than half of breast cancer patients respond to second-line chemotherapy with paclitaxel after failing treatment with anthracyclines such as doxorubicin. A recent clinical trial by Paridaens et al. [J. Clin. Oncol. 18 : 724-733, 2000] examined whether patients may derive a better clinical benefit if paclitaxel was administered before doxorubicin. While overall survival was similar regardless of the order of drug administration, a >4-fold reduction in the response rate to paclitaxel was observed after late … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
57
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 62 publications
(61 citation statements)
references
References 51 publications
4
57
0
Order By: Relevance
“…The resistance indexes for the drugs indicated above were 14.65, 4.36 and 3.18, respectively. This data is consistent with previous study, indicating that cancer cells in culture becoming resistant to a single drug may become resistant to a class of drugs with a similar mechanism of action as well (19). In addition, cancer cells may acquire a cross-resistance to structurally and mechanistically unrelated drugs; this phenomenon is known as MDR.…”
Section: Discussionsupporting
confidence: 92%
“…The resistance indexes for the drugs indicated above were 14.65, 4.36 and 3.18, respectively. This data is consistent with previous study, indicating that cancer cells in culture becoming resistant to a single drug may become resistant to a class of drugs with a similar mechanism of action as well (19). In addition, cancer cells may acquire a cross-resistance to structurally and mechanistically unrelated drugs; this phenomenon is known as MDR.…”
Section: Discussionsupporting
confidence: 92%
“…Another randomized study assessing the strategy of inhibiting P-gp was ineffective but provided some glimpse at Pgp contribution to protecting against taxane central nervous system toxicity (43)(44)(45)(46)(47).…”
Section: Resultsmentioning
confidence: 99%
“…15 For each cell line, 2.5 Â 10 5 cells were placed in a 10-cm tissue culture plate and the cells permitted to grow for 48 h. The cells were released from their plates by trypsin/EDTA treatment, washed twice with phosphate-buffered saline and resuspended in 100 ml of phosphate-buffered saline containing 1% bovine serum albumin (PBA). A 5-ml volume of MRK16 antibody was incubated with the cell suspension for 1 h. The cells were washed twice in PBA and resuspended in 60 ml of PBA.…”
Section: Flow Cytometrymentioning
confidence: 99%